Ensysce Q2 net loss $2.6M; completes Cy Biopharma acquisition adding CY200, $77M funding

Ensysce Biosciences, Inc.

Completed acquisition of Cy Biopharma on Aug 6, 2026, adding CY200 (Orphan Drug-designated for CRPS) as lead asset; up to $77M in new funding.
Q2 2026 net loss $2.6M vs $1.7M; cash $0.7M at June 30, 2026 vs $4.3M at Dec 31, 2025.
Post-quarter-end acquisition and financings provided ~$31M net cash; runway into late 2027, second tranche up to $38.6M on milestones.
R&D expenses $2.5M (up from $1.9M); federal grants $1.2M; NIDA grant third year awarded, total $26M over six years.
Taiwan patent for MPAR through 2042; PF614-301 Phase 3 trial ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.